nach oben

Reactions Weekly

Erschienen in:

01.06.2017 | Case report

Infliximab

Increase in liver function enzymes: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study, a patient [age and sex not stated] was described, who developed increase in liver function enzymes during treatment with infliximab. The patient, who had a history of non-infectious intermediate uveitis, was receiving treatment with infliximab infusion [dosage not stated]. Fifteen months later, the patient experienced a significant increase in liver function enzymes. The treatment with infliximab was discontinued [outcome not stated]. …

Maleki A, et al. Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina 37: 836-843, No. 5, May 2017. Available from: URL: http://doi.org/10.1097/IAE.0000000000001269 - USA

Titel: Infliximab
Increase in liver function enzymes: case report
Publikationsdatum: 01.06.2017
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-017-31595-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Infliximab

Increase in liver function enzymes: case report

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Antithymocyte globulin

Abatacept

Methylprednisolone

Golimumab

Bevacizumab/fluorouracil

Alendronic-acid